Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
0
institutions
Market cap
$5.7M
1M shares
52-week range
$2.96 β $9.85
19% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
www.endrainc.comNo one on the platform currently holds NDRA.
No tracked institution reports a position in NDRA as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-11-07 | 1-for-35reverse |
| 2024-08-20 | 1-for-50reverse |
| 2022-12-09 | 1-for-20reverse |
No one on the platform has traded NDRA yet.
$NDRA valuation check π NDRA currently trades at 3.6x forward sales, well below its recent peak valuation of 6.3x despite advancing toward commercialization of its TAEUS liver imaging platform. As regulatory and commercial milestones begin to unfold, any improvement in execution could support a re-rating toward historical multiples. The current valuation leaves room for upside if the company delivers on adoption and revenue growth. Find more on $NDRA here π https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-39150&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39150
View on StockTwits β$NDRA: What investors should watch heading into Q2 earnings π ENDRA continued operating as a pre-revenue company in Q1 while advancing its TAEUS ultrasound technology toward commercialization. π° Net loss came in at $1.3M, or $1.09 per share, versus $1.0M, or $1.86 per share, in the prior-year quarter. π₯ The quarter was centered on regulatory execution, technology development and laying the groundwork for future market adoption. π As Q2 results approach, investors will be focused on regulatory progress, commercialization timelines, cash runway and any updates on strategic partnerships. Find more on $NDRA here π https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-39050&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39050
View on StockTwits β$NDRA: looking back at the Q1 development story π π The company remained in its pre-revenue stage as it continued advancing its TAEUS platform. π΅ Net loss totaled $1.3M, or $1.09 per share, compared with $1.0M, or $1.86 per share, a year earlier. π₯ Management has remained focused on regulatory progress and preparing TAEUS for broader market adoption. π With Q2 earnings due next month, investors will be looking for updates on regulatory milestones, commercialization plans and financing. Find more on NDRA here π https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38941&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38941
View on StockTwits β$NDRA looks like itβs time to increase share count. Been claiming all the other data for 5 years. FDA not buying it.
View on StockTwits β$NDRA π still watching this one moving slowly
View on StockTwits β$NDRA Q1 2026 Financial Highlights: β’ Cash used in operations improved to $1.1M from $1.3M in Q1 2025. β’ Operating expenses rose to $2.2M from $1.5M, while net loss widened to $1.3M from $1.0M. β’ Ended Q1 with $356K in cash and cash equivalents, plus ~$2.4M held in its Digital Asset Treasury. Find more on NDRA here π https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38835&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38835
View on StockTwits β$NDRA reports another encouraging clinical milestone. π©Ί TAEUS Liver demonstrated MRI-like accuracy in a multi-site validation study. π Key highlights: β 0.90 correlation with MRI-PDFF β AUROC of 0.95β0.99 β ~3% mean error β High reproducibility (ICC 0.89) β Performance remained consistent across operators, sites and BMI ranges. Find more on NDRA here π https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38787&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38787
View on StockTwits β$NDRA Still keeping an eye on this one in the coming days π
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $100000 | +0.0% | $-3.54 | $-3.54β$-3.54 | β | 1 |
| 2027 | $200000 | +100.0% | $-3.04 | $-3.04β$-3.04 | β | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-18 | $-1.23 | $-1.09 | +11.4% |
| 2026-03-31 | $-1.23 | $-3.26 | -165.0% |
| 2025-11-14 | $-1.95 | $-1.75 | +10.3% |
| 2025-08-14 | $-2.27 | $-1.71 | +24.7% |
| 2025-05-15 | $-3.91 | $-2.59 | +33.8% |
| 2025-03-31 | $-4.10 | $-9.40 | -129.3% |
| 2024-11-15 | $-62.30 | $-5.85 | +90.6% |
| 2024-08-22 | $-122.50 | $-139.86 | -14.2% |
| $3139 |
| β |
| GCTKGlucoTrack, Inc. | $0.37 | -3.00% | $3M | β |
| HSCSHeartSciences Inc. | $2.06 | +3.00% | $4M | β |
Source: Financial Modeling Prep Β· peers by sector/industry